$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000119312515280043 Filed on August 06, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$2.045M	$2.083M	$4.801M
YoY Change	15.87%	-56.62%	-11.16%
Cost Of Revenue	$120.0K	$100.0K	$90.00K
YoY Change	33.33%	11.11%	125.0%
Gross Profit	$1.930M	$1.980M	$4.710M
YoY Change	14.88%	-57.96%	-12.13%
Gross Profit Margin	94.38%	95.06%	98.1%
Selling, General & Admin	$2.770M	$3.410M	$2.930M
YoY Change	1.84%	16.38%	1.03%
% of Gross Profit	143.52%	172.22%	62.21%
Research & Development	$4.001M	$2.000M	$3.329M
YoY Change	7.98%	-39.92%	5.13%
% of Gross Profit	207.31%	101.01%	70.68%
Depreciation & Amortization	$40.00K	$40.00K	$30.00K
YoY Change	0.0%	33.33%	-25.0%
% of Gross Profit	2.07%	2.02%	0.64%
Operating Expenses	$4.001M	$2.000M	$3.329M
YoY Change	7.98%	-39.92%	5.13%
Operating Profit	-$4.844M	-$7.369M	-$1.545M
YoY Change	1.91%	377.02%	118.75%
Interest Expense	$827.0K	$843.0K	$949.7K
YoY Change	-11.45%	-11.24%	-0.84%
% of Operating Profit
Other Income/Expense, Net	-$699.0K	-$759.0K	-$351.0K
YoY Change	-15.49%	116.24%	-40.27%
Pretax Income	-$5.540M	-$8.130M	-$1.900M
YoY Change	-0.72%	327.89%	47.29%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$5.543M	-$8.129M	-$1.896M
YoY Change	-0.67%	328.79%	46.52%
Net Earnings / Revenue	-271.05%	-390.25%	-39.48%
Basic Earnings Per Share
Diluted Earnings Per Share	-$215.7K	-$316.7K	-$110.5K
COMMON SHARES
Basic Shares Outstanding	129.6M shares	128.3M shares	85.95M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$93.50M	$99.20M	$55.80M
YoY Change	71.25%	77.78%	-2.28%
Cash & Equivalents	$28.66M	$31.49M	$10.16M
Short-Term Investments	$64.80M	$67.70M	$45.60M
Other Short-Term Assets	$800.0K	$800.0K	$400.0K
YoY Change	14.29%	100.0%	0.0%
Inventory
Prepaid Expenses
Receivables	$2.318M	$2.093M	$4.843M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$96.61M	$102.1M	$60.99M
YoY Change	69.17%	67.33%	4.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$315.5K	$323.1K	$439.4K
YoY Change	-22.56%	-26.46%	-12.28%
Goodwill	$8.982M	$8.982M	$8.982M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$3.300M
YoY Change	-100.0%	-100.0%
Other Assets	$56.03K	$61.72K	$78.31K
YoY Change	-27.76%	-21.19%	-39.66%
Total Long-Term Assets	$9.506M	$9.519M	$12.91M
YoY Change	-14.37%	-26.26%	32.01%
TOTAL ASSETS
Total Short-Term Assets	$96.61M	$102.1M	$60.99M
Total Long-Term Assets	$9.506M	$9.519M	$12.91M
Total Assets	$106.1M	$111.6M	$73.90M
YoY Change	55.57%	50.98%	8.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.569M	$2.385M	$2.849M
YoY Change	8.34%	-16.28%	10.51%
Accrued Expenses	$1.874M	$1.818M	$1.510M
YoY Change	-3.5%	20.43%	6.37%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.860M	$4.846M	$5.499M
YoY Change	-11.97%	-11.86%	302.06%
Total Short-Term Liabilities	$9.303M	$9.050M	$9.925M
YoY Change	-5.4%	-8.82%	85.0%
LONG-TERM LIABILITIES
Long-Term Debt	$20.67M	$21.79M	$24.37M
YoY Change	-12.2%	-10.59%	-16.04%
Other Long-Term Liabilities	$148.7K	$158.5K	$191.1K
YoY Change	-20.64%	-17.03%	-4.03%
Total Long-Term Liabilities	$20.82M	$21.95M	$24.56M
YoY Change	-12.27%	-10.64%	-15.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.303M	$9.050M	$9.925M
Total Long-Term Liabilities	$20.82M	$21.95M	$24.56M
Total Liabilities	$30.12M	$31.00M	$34.49M
YoY Change	-10.26%	-10.12%	-2.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$825.1M	-$819.5M	-$768.3M
YoY Change	6.62%	6.67%	1.79%
Common Stock	$902.5M	$901.6M	$872.3K
YoY Change	103369.27%	103265.65%	5.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.524M	$1.524M	$1.524M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	1.223M shares	1.223M shares	1.223M shares
Shareholders Equity	$75.99M	$80.58M	$39.41M
YoY Change
Total Liabilities & Shareholders Equity	$106.1M	$111.6M	$73.90M
YoY Change	55.57%	50.98%	8.35%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$5.543M	-$8.129M	-$1.896M
YoY Change	-0.67%	328.79%	46.52%
Depreciation, Depletion And Amortization	$40.00K	$40.00K	$30.00K
YoY Change	0.0%	33.33%	-25.0%
Cash From Operating Activities	-$4.480M	-$6.790M	-$4.730M
YoY Change	115.38%	43.55%	-15866.67%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	$0.00	-$60.00K
YoY Change	300.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$2.800M	$15.73M	$6.960M
YoY Change	305.8%	126.01%	-340.83%
Cash From Investing Activities	$2.760M	$15.73M	$6.900M
YoY Change	305.88%	127.97%	-338.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.110M	-920.0K	80.00K
YoY Change	35.37%	-1250.0%	-97.23%
NET CHANGE
Cash From Operating Activities	-4.480M	-6.790M	-4.730M
Cash From Investing Activities	2.760M	15.73M	6.900M
Cash From Financing Activities	-1.110M	-920.0K	80.00K
Net Change In Cash	-2.830M	8.020M	2.250M
YoY Change	27.48%	256.44%	7400.0%
FREE CASH FLOW
Cash From Operating Activities	-$4.480M	-$6.790M	-$4.730M
Capital Expenditures	-$40.00K	$0.00	-$60.00K
Free Cash Flow	-$4.440M	-$6.790M	-$4.670M
YoY Change	114.49%	45.4%	-15666.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	129613751	shares
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10156360
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128390905	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	129613751	shares
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	900338680
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	191659
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	80577001
CY2015Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21790893
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	158533
CY2015Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	500112
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	272550
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17714
CY2015Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	4846338
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2385382
CY2015Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1066732
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1818072
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-819532211
CY2015Q2	us-gaap	Liabilities Liabilities	30999218
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	111576219
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	1296138
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q2	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9049792
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1577
CY2015Q2	us-gaap	Interest Payable Current InterestPayableCurrent	287131
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8319000
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	61715
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7446000
CY2015Q2	us-gaap	Assets Assets	111576219
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17416
CY2015Q2	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	152610
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2093094
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	323101
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	67701055
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2015Q2	us-gaap	Assets Current AssetsCurrent	102056793
CY2015Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	67701055
CY2015Q2	us-gaap	Goodwill Goodwill	8982000
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	777401
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31485243
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12435000
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	67700757
CY2015Q2	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2010Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1612322	shares
CY2010Q1	cris	Direct Offering Purchase Price DirectOfferingPurchasePrice	2.52
CY2010Q1	cris	Registered Direct Offering Number Of Warrant Per Unit RegisteredDirectOfferingNumberOfWarrantPerUnit	1
CY2010Q1	cris	Registered Direct Offering Number Of Common Stock Per Unit RegisteredDirectOfferingNumberOfCommonStockPerUnit	1
CY2010Q1	cris	Registered Direct Offering Units RegisteredDirectOfferingUnits	6449288	shares
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9591487
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86030811	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87253657	shares
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	810001410
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	212548
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	29783626
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	22589058
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	174018
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	122850
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1386226
CY2014Q4	us-gaap	Assets Assets	62613569
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	15880
CY2014Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	152610
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1960995
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4883
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5709985
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2349183
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2007699
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-779555295
CY2014Q4	us-gaap	Liabilities Liabilities	32829943
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62613569
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	872537
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10066867
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10997
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	286075
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	67544
CY2014Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	13877
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	407738
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	42791550
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2014Q4	us-gaap	Assets Current AssetsCurrent	52214909
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	42002782
CY2014Q4	us-gaap	Goodwill Goodwill	8982000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	489844
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7747411
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	788768
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	42802547
CY2014Q4	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2014Q4	cris	Stock Issued During Period Due To Exercise Of Warrants StockIssuedDuringPeriodDueToExerciseOfWarrants	238805	shares
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.70	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.20
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	640000	shares
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.65	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.34
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400000	shares
CY2010Q1	cris	Proceeds From Registered Direct Offering Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts	14942000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10035486
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12763386	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.71	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0185	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.82
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.022	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.70	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85940842	shares
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58861
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	25347887
	us-gaap	Net Income Loss NetIncomeLoss	-7459721
	us-gaap	Revenues Revenues	6085918
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-131908
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1376000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6298130
	us-gaap	Licenses Revenue LicensesRevenue	3000000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1161591
	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	711353
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-69046
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3366224
	us-gaap	Royalty Revenue RoyaltyRevenue	3112183
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13877
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7445336
	us-gaap	Investment Income Interest InvestmentIncomeInterest	90239
	us-gaap	Share Based Compensation ShareBasedCompensation	1427265
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-648876
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	256843
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6474906
	us-gaap	Interest Expense InterestExpense	1900706
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	10343516
	us-gaap	Costs And Expenses CostsAndExpenses	12384048
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	256843
	us-gaap	Royalty Expense RoyaltyExpense	156985
	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	564873
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	395205
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	156377
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5752157
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	52427
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	105000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-2575765
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	74837
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	35736387
	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	-54762
	cris	Research And Development Revenue Net ResearchAndDevelopmentRevenueNet	-26265
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b><u>Nature of Business</u></b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 56px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 56px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company conducts its research and development programs both internally and through strategic collaborations. The Company’s most advanced drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K enzymes.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 56px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In January 2015, the Company entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene (see Note 4(b)). The collaboration provides for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program. The first two programs under the collaboration are focused on the development of orally-available small molecule antagonists of programmed death ligand-1 (PD-L1) in the immuno-oncology field and orally-available small molecule inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4) in the precision oncology field.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 56px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company’s collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge® (vismodegib), a first-in-class orally-administered small molecule Hedgehog pathway inhibitor, in advanced basal cell carcinoma, or BCC. Roche and Genentech are also continuing Erivedge’s clinical development in less severe forms of BCC as well as planned development in other non-oncology indications.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 56px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company’s proprietary pipeline also includes CUDC-427, an orally-available, small molecule antagonist of inhibitor of apoptosis, or IAP proteins, and CUDC-305, a Heat Shock Protein 90, or HSP90, inhibitor. The Company currently intends to utilize its available resources for the continued development of CUDC-907 and drug candidates under a collaboration with Aurigene. As such, Curis is seeking to collaborate with third parties for the further development of CUDC-427 and CUDC-305.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 56px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 56px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company is subject to risks common to companies in the biotechnology industry as well as risk that are specific to the Company’s business, including, but not limited to: the Company’s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the Company’s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties’ collaboration agreement; the Company’s ability to advance and expand its research and development programs; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company’s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.à r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 56px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company’s future operating results will largely depend on the magnitude of payments that it receives and makes under its current and potential future corporate collaborations and the progress of drug candidates currently in its development pipeline. The results of the Company’s operations will vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: Roche and Genentech’s ability to successfully commercialize Erivedge; positive results in Roche and Genentech’s ongoing clinical trials; Aurigene’s ability to successfully discover and develop preclinical programs under the Company’s collaboration with Aurigene, as well as the Company’s decision to exclusively license and further develop programs under this collaboration; the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; and the Company’s ability to successfully enter into one or more material outlicensing or collaboration agreements for its proprietary drug candidates.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 56px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company anticipates that existing cash, cash equivalents and investments at June 30, 2015 should enable it to maintain current and planned operations into 2017. The Company’s ability to continue funding its planned operations beyond this period is dependent upon, among other things, the success of its collaborations with Genentech and the Leukemia & Lymphoma Society, or LLS, including its receipt of additional contingent cash payments under these collaborations; its ability to control expenses and its ability to raise additional funds through equity or debt financings, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14545454
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13552649	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.70	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.94
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	0	shares
	dei	Entity Registrant Name EntityRegistrantName	CURIS INC
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0150	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.71
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.019	pure
	dei	Trading Symbol TradingSymbol	CRIS
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.68	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118199388	shares
	us-gaap	Revenue Recognition Milestone Method Milestone RevenueRecognitionMilestoneMethodMilestone	The Company has agreed to make each of the following one-time payments to Debiopharm (i) $3,000,000 within 30 days after the first dosing of the first patient in the first Phase 3 clinical trial of Debio 0932; and (ii) $10,000,000 within 30 days after receipt of the first marketing approval for Debio 0932 in the United States of America or any specified major European market (whichever occurs first).
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	Segment
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14957
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	66295557
	us-gaap	Net Income Loss NetIncomeLoss	-39976916
	us-gaap	Revenues Revenues	3740836
	us-gaap	Repayments Of Debt RepaymentsOfDebt	1677479
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	273826
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1529000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38390965
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	16545
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1585951
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	47123
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	132099
	us-gaap	Royalty Revenue RoyaltyRevenue	3704906
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13877
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39967496
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	247628
	us-gaap	Investment Income Interest InvestmentIncomeInterest	124363
	us-gaap	Share Based Compensation ShareBasedCompensation	1973701
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	195400
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10656948
	us-gaap	Interest Expense InterestExpense	1710314
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-24854042
	us-gaap	Costs And Expenses CostsAndExpenses	42131801
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	63137328
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	64619407
	us-gaap	Royalty Expense RoyaltyExpense	187064
	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	23737832
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-153956
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	241655
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6939974
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	30730
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	75000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	25431462
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	82397
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	41442595
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	24347815
	cris	Class Of Warrant Expired ClassOfWarrantExpired	1373517	shares
	cris	Royalties Terms Of Collaboration Agreement RoyaltiesTermsOfCollaborationAgreement	The term of the collaboration agreement begins upon signing and, unless earlier terminated, will expire upon either (i) 90 days after the completion by Aurigene of its obligations under all research plans if the Company has not exercised the option with respect to at least one program by such time; or (ii) expiration of the last-to-expire royalty term for any and all products.
	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	Plans
	cris	Issuance Of Common Stock To Licensees IssuanceOfCommonStockToLicensees	23968183
	cris	Compensation Expenses Related To Agreement CompensationExpensesRelatedToAgreement	750000
	cris	Class Of Warrant Or Right Expiration Date ClassOfWarrantOrRightExpirationDate	2015-01-27
	cris	Research And Development Revenue Net ResearchAndDevelopmentRevenueNet	35930
	cris	Estimated Loan Repayment Period EstimatedLoanRepaymentPeriod	2019
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	25090908	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	64619407
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.09
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	640000	shares
CY2015Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	20000000
CY2015Q1	cris	Percentage Of Royalty On Net Sales PercentageOfRoyaltyOnNetSales	0.03	pure
CY2015Q1	cris	Non Royalty Consideration Percentage NonRoyaltyConsiderationPercentage	0.15	pure
CY2015Q1	cris	Percentage Of Royalty To Be Received PercentageOfRoyaltyToBeReceived	0.10	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.75
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1040000	shares
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12763386	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85963836	shares
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-1895785
CY2014Q2	us-gaap	Revenues Revenues	4801285
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1544787
CY2014Q2	us-gaap	Licenses Revenue LicensesRevenue	3000000
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-350998
CY2014Q2	us-gaap	Royalty Revenue RoyaltyRevenue	1823935
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1885634
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	41479
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	683821
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-557253
CY2014Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3328976
CY2014Q2	us-gaap	Interest Expense InterestExpense	949730
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	6346072
CY2014Q2	us-gaap	Royalty Expense RoyaltyExpense	91837
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	108366
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2925259
CY2014Q2	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	-110434
CY2014Q2	cris	Research And Development Revenue Net ResearchAndDevelopmentRevenueNet	-22650
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13552649	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	128351482	shares
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-8128693
CY2015Q2	us-gaap	Revenues Revenues	2082504
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7369416
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-759277
CY2015Q2	us-gaap	Royalty Revenue RoyaltyRevenue	2033836
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8127868
CY2015Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	127470
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	84092
CY2015Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1022598
CY2015Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2015Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5937976
CY2015Q2	us-gaap	Interest Expense InterestExpense	843369
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	9451920
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000
CY2015Q2	us-gaap	Royalty Expense RoyaltyExpense	102972
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	120828
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3410972
CY2015Q2	cris	Research And Development Revenue Net ResearchAndDevelopmentRevenueNet	48668

Files In Submission

Name	View Source	Status
0001193125-15-280043-index-headers.html	Edgar Link	pending
0001193125-15-280043-index.html	Edgar Link	pending
0001193125-15-280043.txt	Edgar Link	pending
0001193125-15-280043-xbrl.zip	Edgar Link	pending
cris-20150630.xml	Edgar Link	completed
cris-20150630.xsd	Edgar Link	pending
cris-20150630_cal.xml	Edgar Link	unprocessable
cris-20150630_def.xml	Edgar Link	unprocessable
cris-20150630_lab.xml	Edgar Link	unprocessable
cris-20150630_pre.xml	Edgar Link	unprocessable
d938892d10q.htm	Edgar Link	pending
d938892dex101.htm	Edgar Link	pending
d938892dex311.htm	Edgar Link	pending
d938892dex312.htm	Edgar Link	pending
d938892dex321.htm	Edgar Link	pending
d938892dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2015 Q3 Form 10-Q Financial Statement

#000119312515280043 Filed on August 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2015 Q3 Form 10-Q Financial Statement

#000119312515280043 Filed on August 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris